Tag: cardiotonic agents market growth

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The Cardiotonic Agents Market Growth Evolved From 2024 To 2025, And What’s Ahead?

In recent times, the market size of cardiotonic agents has seen rapid expansion. The growth is set to continue, with the market expected to expand from $2.78 billion in 2024 to $3.11 billion in 2025, reflecting a compound annual growth rate (CAGR) of 11.9%. The historical period witnessed this growth due to several factors, including a rise in heart failure cases, an increase in the elderly population, a higher incidence of coronary artery disease, the adoption of more sedentary lifestyles, and the escalating burden of hypertension and diabetes.

There is a predicted sharp incline in the cardiotonic agents market size in the coming years, with an increase to $4.95 billion estimated by 2029 and a compound annual growth rate (CAGR) of 12.3%. The spike in size for the predicted time frame is contingent on factors such as the escalation in cardiovascular death rates, the increase in clinical trials tailored towards advancing cardiotonic formulations, enhanced cooperations between the public and private sector in cardiovascular drug invention, rising hospital admittance due to cardiac issues, and a heightened demand for individualized cardiovascular medicine. Some significant trends in the forecast period encompass the production of peptide-based cardiotonic agents, the creation of drugs with dual-mechanisms, the incorporation of pharmacogenomics, reinvention of injectable depot formulations, and introduction of combined therapies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24184&type=smp

Which Factors and External Forces Are Driving Demand in the Cardiotonic Agents Market?

The increase in cardiovascular disease incidence is anticipated to significantly drive the cardiotonic agents market’s expansion. Cardiovascular diseases, or CVDs, comprise various disorders impacting the heart and blood vessels, including coronary artery disease, heart failure, arrhythmia, and stroke. These conditions are often attributable to unhealthy eating habits that are high in saturated and trans fats, salt, and additional sugars, leading to obesity, hypertension, and high cholesterol levels. By enhancing the efficacy and contraction potency of the heart muscle, cardiotonic agents aid in better blood flow and alleviate symptoms in multiple cardiovascular diseases. For example, doctor-certified deaths due to coronary heart disease (CHD) in Australia escalated from 14,100 cases in 2021 to 14,900 cases in 2022, as cited by the Australian Institute of Health and Welfare in December 2023. Hence, the cardiotonic agents market is experiencing growth due to the climbing rates of cardiovascular ailments.

Which Segments in the Cardiotonic Agents Offer the Most Growth?

The cardiotonic agents market covered in this report is segmented –

1) By Drug Type: Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents, Other Drug Types

2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations

3) By Dosage Form: Tablet, Solution, Other Dosage Forms

4) By Application: Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension, Other Applications

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Digitalis Glycoside: Digoxin, Digitoxin, Lanatoside C

2) By Phosphodiesterase Inhibitors: Milrinone, Enoximone, Amrinone

3) By Cardioprotectants: Coenzyme Q10, Dexrazoxane, Trimetazidine

4) By Sympathomimetic Agents: Dobutamine, Dopamine, Norepinephrine

5) By Other Drug Types: Levosimendan, Omecamtiv Mecarbil, Cilostazol

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=24184&type=smp

What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Cardiotonic Agents Market?# Market?

North America was the largest region in the cardiotonic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiotonic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Cutting-Edge Market Trends Are Expected to Drive theCardiotonic Agents Market’s Growth?

Significant players in the cardiotonic agents market, such as Hikma Pharmaceuticals plc, are concentrating their efforts on the creation of innovative products like short-term inotropic drugs. These drugs are designed to boost cardiac performance in cases of acute heart failure or cardiogenic shock. Such drugs temporarily intensify the heart’s contraction power, leading to an improved cardiac output. In June 2023, Hikma Pharmaceuticals plc, a pharmaceutical company based in the UK, introduced a Dobutamine Injection, USP, in a 250 mg/20 mL vial. This injection is primarily used in adults suffering from cardiac decompensation due to a decrease in heart contractility, usually as a result of heart disease or post cardiac surgery. The injection, which functions by stimulating the beta-1 receptors, rapidly enhances heart muscle contraction and cardiac output (in just 1–2 minutes). Administered intravenously, the injection is generally given in a closely monitored hospital environment.

View the full report here:

https://www.thebusinessresearchcompany.com/report/cardiotonic-agents-global-market-report

What Are the Key Elements That Define the Cardiotonic Agents Market?

Cardiotonic agents are a class of drugs that improve the efficiency and contraction of the heart muscle, improving its ability to pump blood. These agents are used to treat heart failure and certain arrhythmias by increasing cardiac output and improving circulation.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24184

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Cardiotonic Agents Market Size Changed, over the years?

The market for cardiotonic agents has seen a quick expansion in recent times. Its size is predicted to increase from $2.78 billion in 2024 to $3.14 billion in 2025, at a compound annual growth rate (CAGR) of 12.9%. The significant growth during the historic period can be owed to various factors such as a higher frequency of heart failure, an aged population that is increasing, a greater incidence of coronary artery disease, a rise in sedentary lifestyles adoption, and increased pressure of hypertension and diabetes.

How Much Will the Cardiotonic Agents Market Be Worth in 2029?

The market for cardiotonic agents is predicted to witness accelerated expansion in the approaching years, with a projection to reach $5.06 billion by 2029, boasting a compound annual growth rate (CAGR) of 12.6%. This remarkable surge in the predicted period can be credited to the escalation in cardiovascular death rates, increasing clinical tests focused on enhancing cardiotonic formulations, growth of public-private collaborations in the development of cardiovascular drugs, an influx in hospital admissions due to heart-related issues, and a rising demand for personalized cardiovascular treatment. Key trends in the projected period comprise the development of peptide-based cardiotonic agents, evolution of dual-mechanism drugs, the inclusion of pharmacogenomics, advancements in injectable depot formulations, and the innovation of combination therapies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24184&type=smp

Which is the Largest Company in the Cardiotonic Agents Market?

Major companies operating in the cardiotonic agents market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Fresenius Kabi, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Alchem International Private Ltd, Farbe Firma Private Limited, Salius Pharma Pvt. Ltd., Johnlee Pharmaceuticals Pvt. Ltd., Healthy Life Pharma Pvt Ltd, Anwita Drugs, Varion Lifesciences, Deccan Nutraceuticals Pvt. Ltd.

What Are the Main Market Drivers in the Cardiotonic Agents Industry?

The cardiotonic agents market is expected to expand due to the escalating prevalence of cardiovascular diseases. These diseases encompass disorders impacting the heart and blood vessels, with coronary artery disease, heart failure, arrhythmias, and stroke among them. The unhealthy eating habits, replete with saturated fats, trans fats, salt, and extra sugars, lead to conditions such as obesity, high blood pressure, and high cholesterol levels, thereby causing a surge in cardiovascular diseases. Cardiotonic agents enhance the heart muscle’s efficiency and contraction strength, leading to better blood circulation and diminished symptoms of various cardiovascular diseases. In December 2023, as per the Australian Institute of Health and Welfare, a governmental agency in Australia, there was a rise in doctor-certified deaths due to coronary heart disease (CHD) from 14,100 in 2021 to 14,900 in 2022. Hence, the increasing prevalence of cardiovascular diseases is fueling the cardiotonic agents market’s growth.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24184&type=smp

How Is the Cardiotonic Agents Market Segments Structured?

The cardiotonic agents market covered in this report is segmented –

1) By Drug Type: Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents, Other Drug Types

2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations

3) By Dosage Form: Tablet, Solution, Other Dosage Forms

4) By Application: Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension, Other Applications

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Digitalis Glycoside: Digoxin, Digitoxin, Lanatoside C

2) By Phosphodiesterase Inhibitors: Milrinone, Enoximone, Amrinone

3) By Cardioprotectants: Coenzyme Q10, Dexrazoxane, Trimetazidine

4) By Sympathomimetic Agents: Dobutamine, Dopamine, Norepinephrine

5) By Other Drug Types: Levosimendan, Omecamtiv Mecarbil, Cilostazol

What Strategic Trends Are Transforming the Cardiotonic Agents Market?

Prominent entities in the cardiotonic agents market are concentrating on the creation of novel products such as short-term inotropic medications to ameliorate cardiovascular performance in severe heart failure and cardiogenic shock scenarios. These drugs are utilized to momentarily augment the contraction ability of the heart, leading to improved cardiac output. As an illustration, in June 2023, Hikma Pharmaceuticals plc, a pharmaceutical firm based in the UK, introduced Dobutamine Injection, USP, packaged in a 250 mg/20 mL vial. This injection is employed for short-term inotropic support in adults undergoing cardiac decompensation resulting from diminished heart contractility, usually a consequence of heart disease or post-cardiac surgery. The mode of action involves stimulating beta-1 receptors to boost muscle contractility of the heart and cardiac output swiftly (within 1–2 minutes). The injection is given intravenously and typically administered in a hospital environment under close observation.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cardiotonic-agents-global-market-report

Which Global Regions Offer the Highest Growth in the Cardiotonic Agents Market?

North America was the largest region in the cardiotonic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiotonic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/customise?id=24184&type=smp

This Report Delivers Insight On:

1. How big is the cardiotonic agents market, and how is it changing globally?

2. Who are the major companies in the cardiotonic agents market, and how are they performing?

3. What are the key opportunities and risks in the cardiotonic agents market right now?

4. Which products or customer segments are growing the most in the cardiotonic agents market?

5. What factors are helping or slowing down the growth of the cardiotonic agents market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

We’ve updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Are the Key Projections for the CAGR of the Cardiotonic Agents Market Size From 2025 to 2034?

The market size of cardiotonic agents has seen swift expansion in the recent past. The market is projected to increase from $2.78 billion in 2024 to $3.14 billion in 2025, boasting a compound annual growth rate (CAGR) of 12.9%. Factors contributing to this growth during the historic period include the rising number of heart failure cases, an aging population, increased cases of coronary artery disease, growing prevalence of inactive lifestyles, as well as an increasing burden of hypertension and diabetes.

In the coming years, the cardiotonic agents market is projected to experience significant growth. By 2029, it’s anticipated to reach $5.06 billion, with a compound annual growth rate (CAGR) of 12.6%. Factors such as increased cardiovascular mortality rates, expanding clinical tests for enhanced cardiotonic formulations, increased public-private collaboration in cardiovascular drug production, growing hospital admissions resulting from cardiac issues, and a rising trend for personalized cardiovascular treatment contribute to growth in the forecast period. Key trends predicted during this period include the development of peptide-based cardiotonic agents and dual-mechanism drugs, the application of pharmacogenomics, innovative injectable depot formulations, and combination therapies innovation.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24184&type=smp

Which Primay Drivers Are Accelerating Growth in the Cardiotonic Agents Market?

The anticipated surge in cardiovascular disorders is predicted to significantly boost the cardiotonic agents market moving forward. Cardiovascular diseases (CVDs) encompass a variety of disorders influencing the heart and blood vessels, such as coronary artery disease, heart failure, arrhythmias, and stroke. The increase in CVDs is predominantly due to unhealthful diets loaded with saturated fats, trans fats, salt, and added sugars, resulting in obesity, hypertension, and high cholesterol levels. Cardiotonic agents bolster the efficacy and the contraction power of the heart muscle, thereby enhancing blood circulation and alleviating symptoms in multiple cardiovascular conditions. For instance, as per the data from the Australian Institute of Health and Welfare in December 2023, a government agency based in Australia, medically verified fatalities due to coronary heart disease (CHD) in Australia rose from 14,100 in 2021 to 14,900 in 2022. As such, the escalating prevalence of cardiovascular disorders is stimulating the expansion of the cardiotonic agents market.

Which Primary Segments of the Cardiotonic Agents Market Are Driving Growth and Industry Transformations?

The cardiotonic agents market covered in this report is segmented –

1) By Drug Type: Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents, Other Drug Types

2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations

3) By Dosage Form: Tablet, Solution, Other Dosage Forms

4) By Application: Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension, Other Applications

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Digitalis Glycoside: Digoxin, Digitoxin, Lanatoside C

2) By Phosphodiesterase Inhibitors: Milrinone, Enoximone, Amrinone

3) By Cardioprotectants: Coenzyme Q10, Dexrazoxane, Trimetazidine

4) By Sympathomimetic Agents: Dobutamine, Dopamine, Norepinephrine

5) By Other Drug Types: Levosimendan, Omecamtiv Mecarbil, Cilostazol

Request customized data on this market:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24184&type=smp

Which Regions Are Key Players in the Growth of the Cardiotonic Agents Market?

North America was the largest region in the cardiotonic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiotonic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Technological Trends Are Reshaping the Cardiotonic Agents Industry Dynamics?

The primary players in the cardiotonic agents market are directing their efforts towards the development of novel products like short-term inotropic drugs, designed to boost heart function during acute heart failure and cardiogenic shock. These short-term inotropic medicines serve to augment the heart’s contractile ability in the short run, thereby enhancing cardiac output. For example, Dobutamine Injection, USP, in a 250 mg/20 mL vial, was introduced by UK-based pharmaceutical firm Hikma Pharmaceuticals plc in June 2023. This injection is intended for the short-term inotropic aid in adults suffering from cardiac decompensation due to diminished heart contractility, which is commonly a consequence of heart disease or post-cardiac surgery. It operates by triggering beta-1 receptors, thereby increasing the contractility of the heart muscle and cardiac output swiftly (1–2 minutes). This injection is typically given in a hospital under close supervision and is administered intravenously.

View the full report here:

https://www.thebusinessresearchcompany.com/report/cardiotonic-agents-global-market-report

What Parameters Are Used to Define the Cardiotonic Agents Market?

Cardiotonic agents are a class of drugs that improve the efficiency and contraction of the heart muscle, improving its ability to pump blood. These agents are used to treat heart failure and certain arrhythmias by increasing cardiac output and improving circulation.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/customise?id=24184&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model